Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2022-08-08 Director's Dealing
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
Disclosure of Dealings under Rule 22 of the Takeovers Code
Director's Dealing Classification · 95% confidence The document is a Public Disclosure Form reporting dealings in shares of Yankuang Energy Group Company Limited. It references Rule 22 of the Hong Kong Code on Takeovers and Mergers, indicating it is related to insider or director share transactions. The content details the nature of securities dealings, including purchase amounts and prices. The document is short (1463 characters) and focuses solely on share transactions by a connected party. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives or connected parties. There is no indication of a full report, financial data, or other types of filings. Therefore, the correct classification is DIRS with high confidence.
2022-08-08 English
VOLUNTARY ANNOUNCEMENT - CSTONE PRESENTS UPDATED RESULTS OF A REGISTRATIONAL STUDY OF SUGEMALIMAB IN PATIENTS WITH STAGE III NSCLC VIA ORAL PRESENTATION AT WCLC 2022
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CStone Pharmaceuticals presenting updated clinical study results of sugemalimab in patients with stage III NSCLC. It details the final progression-free survival analysis from a registrational study (GEMSTONE-301) presented at a medical conference (WCLC 2022). The content focuses on clinical trial results, efficacy, safety, and regulatory approvals related to the drug. There are no financial statements, earnings data, management discussion of financial results, or regulatory certifications. The document is not an annual or interim report, nor is it a call transcript or capital update. It is a detailed announcement of clinical trial results and regulatory status, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other specific categories such as Earnings Release or Investor Presentation. The document length is over 11,000 characters, so it is not a brief report publication announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-08-08 English
Disclosure of Dealings under Rule 22 of the Takeovers Code
Director's Dealing Classification · 100% confidence The document is a Public Disclosure Form reporting dealings in shares of Yankuang Energy Group Company Limited. It references securities dealings pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers, detailing purchase transactions by China International Capital Corporation Limited. The content focuses on insider or related party share transactions rather than financial results, management changes, or regulatory announcements. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives or related parties. The document length is short and specific to share dealings, confirming the classification as DIRS.
2022-08-05 English
Disclosure of Dealings under Rule 22 of the Takeovers Code
Director's Dealing Classification · 100% confidence The document is a Public Disclosure Form reporting dealings in shares of Yankuang Energy Group Company Limited. It includes details of securities transactions such as purchase date, number of shares, prices paid, and nature of dealings. The document references compliance with Rule 22 of the Hong Kong Code on Takeovers and Mergers, which relates to disclosures of share transactions by insiders or connected parties. The content is focused on reporting insider or related party share transactions rather than financial results, management changes, or other corporate events. Therefore, it fits the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives or connected parties.
2022-08-04 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2022
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return on movements in securities for CStone Pharmaceuticals, including authorized share capital, issued shares, share options, and confirmations related to share issuance. It is submitted to the Hong Kong Exchanges and Clearing Limited and covers the month ended 31 July 2022. The content focuses on share capital changes, share options exercised, and confirmations of compliance with listing rules. This type of document is a regulatory filing reporting share capital movements and share issuance details, not a full financial report or earnings release. It does not fit categories like Annual Report, Earnings Release, or Management Reports. It is not a proxy solicitation or voting results announcement. It is a regulatory compliance filing specific to share capital movements and confirmations. Therefore, the best fitting category is Regulatory Filings (RNS). The document length (9039 characters) and detailed content support this classification with high confidence.
2022-08-03 English
Disclosure of Dealings under Rule 22 of the Takeovers Code
Director's Dealing Classification · 100% confidence The document is titled 'Public Disclosure Form' and details securities dealings by China International Capital Corporation Limited in shares of Yankuang Energy Group Company Limited. It references Rule 22 of the Hong Kong Code on Takeovers and Mergers, indicating it relates to insider or connected party share transactions. The content is a report of personal share transactions by a company director or connected party, which fits the definition of Director's Dealing filings. The document length is short and focused solely on share dealings, with no financial results or other report content. Therefore, the appropriate classification is Director's Dealing (DIRS).
2022-08-03 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.